CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
The purpose of the study is to evaluate the safety and tolerability of the study drug, calaspargase pegol, when given with multi-agent chemotherapy.
Trial Details
- NCT ID
- NCT05581030
- Phase
- PHASE1
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Status
- RECRUITING
- Cancer Type
- Leukemia
- Interventions
- Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy)
- Calaspargase Pegol
- Rituximab
- Locations (sample)
- Tampa, Florida, United States|27.94752,-82.45843
Key Eligibility Criteria
- Pathologically confirmed Philadelphia negative B- or T-cell acute lymphoblastic leukemia, with \>10% peripheral blood or bone marrow lymphoblasts a…
- Treatment and full recovery from arm 1A of the Hyper-CVAD regimen.
- Be willing and able to provide written informed consent/assent for the trial.
- Able to adhere to the study visit schedule and other protocol requirements.
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Leukemia Trials on Trialify →